New drug cocktail aims to tackle Hard-to-Treat stomach cancer

NCT ID NCT07680569

Not yet recruiting Disease control Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study tests a new biologic drug called HCB101 in combination with other cancer drugs (zolbetuximab and chemotherapy) for people with advanced gastric or gastro-esophageal cancer. The goal is to find a safe dose and see if the combination can shrink tumors. About 40 adults will take part, and the study will monitor side effects and how well the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HCB101 (a biologic drug) combined with zolbetuximab and chemotherapy (oxaliplatin, 5-fluorouracil, leucovorin)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced gastric or gastro-esophageal cancer that has not responded to standard therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so the benefits are uncertain. Side effects from the drug combination may be significant, and the treatment may not shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GC/GEJC

More trials for these conditions

Other studies related to the condition(s) this trial covers.